A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/ hyperactivity disorder in Spain

BMC Psychiatry

Volumn 9, Issue , 2009, Pages

  Hong, Jihyung ^a,b   Dilla, Tatiana ^c   Arellano, Jorge ^b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c ELI LILLY AND COMPANY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; CENTRAL STIMULANT AGENT; PROPYLAMINE;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HUMAN; INSOMNIA; QUALITY ADJUSTED LIFE YEAR; SPAIN; ADOLESCENT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ECONOMICS; EVALUATION; PROBABILITY; STATISTICAL MODEL;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CONTROLLED CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; METHYLPHENIDATE; MODELS, ECONOMIC; PROPYLAMINES; SPAIN;

EID: 65449173644     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-9-15     Document Type: Article

References (52)

1. Faraone SV Sergeant J Gillberg C Biederman J The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry 2003, 2(2):104-113 1525089 16946911
2. Jensen PS Garcia JA Glied S Crowe M Foster M Schlander M Hinshaw S Vitiello B Arnold LE Elliott G et al Cost-effectiveness of ADHD treatments: Findings from the multimodal treatment study of children with ADHD Am J Psychiatry 2005, 162(9):1628-1636 10.1176/ appi.ajp.162.9.1628 16135621
3. Biederman J Attention-deficit/hyperactivity disorder: A life-span perspective J Clin Psychiatry 1998, 59(Suppl 7):4-16 9680048
4. Biederman J Mick E Farone SV Age-dependent decline of symptoms of attention-deficit hyperactivity disorder: Impact of remission definition and symptom type Am J Psychiatry 2000, 157:816-818 10.1176/ appi.ajp.157.5.816 10784477
5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Washington, DC: American Psychiatric Press 4 2000
6. Kratochvil CJ Newcorn JH Arnold E Duesenberg D Emslie G Quintana H E H Wagner KD Gao H Michelson D Biederman J Atomoxetine Alone or Combined With Fluoxetine for Treating ADHD With Comorbid Depressive or Anxiety Symptoms J AM Acad Adolesc Psychiatry 2005, 44(9):915-924 10.1097/ 01.chi.0000169012.81536.38
7. Banaschewski T Roessner V Dittmann RW Santosh P Rothenberger A Non-stimulant medications in the treatment of ADHD Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):I102-I116 15322961
8. Downey KK Stelson FW Pomerleau OF Giodani B Adult attention deficit hyperactivity disorder: Psychological test profiles in a clinical population J Nerv Ment Dis 1997, 185:32-38 10.1097/ 00005053-199701000-00006 9040531
9. Barkley RA Guevremont DC Anastopoulos AD DuPaul GJ Shelton TL Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: A 3- to 5-year follow-up survey Pediatrics 1993, 92(2):212-218 8337019
10. Mannuzza S Klein RG Bonagura N Malloy P Giampino TL Addalli KA Hyperactive boys almost grown up. V. Replication of psychiatric status Arch Gen Psychiatry 1991, 48(1):77-83 1984764
11. Mannuzza S Klein RG Bessler A Malloy P LaPadula M Adult psychiatric status of hyperactive boys grown up Am J Psychiatry 1998, 155(4):493-498 9545994
12. Hart EL Lahey BB Loeber R Applegate B Frick PJ Developmental change in attention-deficit hyperactivity disorder in boys: A four-year longitudinal study J Abnorm Child Psychol 1995, 23(6):729-749 10.1007/ BF01447474 8609310
13. Rasmussen P Gillberg C Natural outcome of ADHD with developmental coordination disorder at age 22 years: A controlled, longitudinal, community-based study J Am Acad Child Adolesc Psychiatry 2000, 39(11):1424-1431 10.1097/00004583-200011000-00017 11068898
14. Harpin VA The effect of ADHD on the life of an individual, their family, and community from preschool to adult life Arch Dis Child 2005, 90(Suppl 1):i2-7 1765272 15665153 10.1136/adc.2004.059006
15. Alvarez C Barriento R Variability and tendencies in the consumption of methylphenidate in Spain. An estimation of the prevalence of attention deficit hyperactivity disorder Rev Neurol 2003, 37:806-810 14606045
16. Garcia-Jimenez MC Lopez-Pison J Blasco-Arellano MM The primary care paediatrician in attention deficit hyperactivity disorder. An approach involving a population study Rev Neurol 2005, 41(2):75-80 16028184
17. Cardo E Servera M Llobera J Estimation of the prevalence of attention deficit hyperactivity disorder among the standard population on the island of Majorca Rev Neurol 2007, 44(1):10-14 17199223
18. National Institute for Health and Clinical Excellence (NICE) TA98 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents:gUidance http://wwwniceorguk/Guidance/TA98/Guidance/pdf/English [Accessed July 31, 2007]
19. Escobar R Soutullo C Sebastian S Fernandez E Julian I Lahortiga F Atomoxetine safety and efficacy in children with attention deficit/ hyperactivity disorder (ADHD): Initial phase of 10-week treatment in a relapse prevention study with a Spanish sample Actas Esp Psiquiatr 2005, 33(1):26-32 15704028
20. Harpin VA Medication options when treating children and adolescents with ADHD: Interpreting the NICE guidance 2006 Arch Dis Child Educ Pract Ed 2008, 93(2):58-65 10.1136/adc.2006.106864 18356307
21. King S Griffin S Hodges Z Weatherly H Asseburg C Richardson G Golder S Taylor E Drummond M Riemsma R A systematicreview and economic model of the effectiveness and cost-effectivenessof methylphenidate, dexamfetamine and atomoxetine for the treatmentof attention deficit hyperactivity disorder in children andadolescents Health Technol Assess 2006, 10(23):iIi-iv xiii 146 16796929
22. Schlander M Health Technology Assessments by the National Institute for Health and Clinical Excellence. A Qualitative Study New York: Springer 2007
23. Kelsey DK Sumner CR Casat CD Once-Daily Atomoxetine Treatment for Children With Attention-Deficit/Hyperactivity Disorder, Including an Assessment of Evening and Morning Behavior: A Double-Blind, Placebo-Controlled Trial Paediatrics 2004, 114:1-8 10.1542/peds.114.1.e1
24. Pelham WE Gnagy EM Burrows-Maclean L Williams A Fabiano GA Morrisey SM Chronis AM Forehand GL Nguyen CA Hoffman MT et al Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings Pediatrics 2001, 107:6 E105 10.1542/peds.107.6.e105 11389303
25. Swanson J Gupta S Lam A Shoulson I Lerner M Modi N Lindemulder E Wigal S Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies Arch Gen Psychiatry 2003, 60(2):204-211 10.1001/archpsyc.60.2.204 12578439
26. Wolraich ML Greenhill LL Pelham W Swanson J Wilens T Palumbo D Atkins M McBurnett K Bukstein O August G Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/ hyperactivity disorder Pediatrics 2001, 108(4):883-892 10.1542/ peds.108.4.883 11581440
27. Cottrell S Tilden D Robinson P Bae J Arellano J Edgell E Aristides M Boye KS A Modeled Economic Evaluation ComparingAtomoxetine with Stimulant Therapy in the Treatment of Children withAttention-Deficit/ Hyperactivity Disorder in the United Kingdom Value Health 2008, 11(3):376-388 doi:10.1111/j.1524-4733 18489664
28. Brown TE Emerging Understanding of Attention-Deficit Disorders and Comorbidities in Attention-Deficit Disorders and Comorbidities in Children, Adolescents, and Adult Washington, DC: American Psychiatric Press 2000
29. Electronic Medicines Compendium (eMC) [Online] http://www.medicines.org.uk/emc.aspx
30. Newcorn JH Zhang S Rogers AK Levine LR Atomoxetine treatment response in ADHD patients naive to previous pharmacotherapy [abstract] American Academy of Child and Adolescent Psychiatry 51th Annual Meeting; October 19-24, 2004, Washington DC
31. Efron D Jarman F Barke M Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial Pediatrics 1997, 100(6):E6 10.1542/peds.100.6.e6 9382907
32. TreeAge Software. Inc TreeAge Software: TreeAge Pro2007 Williamstown MA 2007
33. Sonnenberg FA Beck R Markov Models in Medical Decision Marking: A Practical Guide Med Decis Making 1993, 13:322-338 10.1177/ 0272989X9301300409 8246705
34. Base de datos del Medicamentos [Drug database] http://www.portalfarma.com/
35. Concerta TM (Summary Products Characteristics)[Online] https://sinaem4.agemed.es/consaem/
36. Rubifen TM (Summary Products Characteristics)[Online] https://sinaem4.agemed.es/consaem/
37. Secnik K Matza LS Cottrell S Edgell E Tilden D Mannix S Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom Med Decis Making 2005, 25(1):56-70 10.1177/0272989X04273140 15673582
38. Michelson D Faries D Wernicke J Kelsey D Kendrick K Sallee FR Spencer T Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study Pediatrics 2001, 108(5):E83 10.1542/peds.108.5.e83 11694667
39. Spencer T Heiligenstein JH Biederman J Faries DE Kratochvil CJ Conners CK Potter WZ Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder J Clin Psychiatry 2002, 63(12):1140-1147 12523874
40. Michelson D Allen AJ Busner J Casat C Dunn D Kratochvil C Newcorn J Sallee FR Sangal RB Saylor K et al Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study Am J Psychiatry 2002, 159(11):1896-1901 10.1176/appi.ajp.159.11.1896 12411225
41. Kurlan R Allen AJ Gilbert D Linder S Lewis D Winner P Dunn D Sallee FR Milton D Mintz M et al Atomoxetine Treatment In Children With ADHD And Comorbid Tic Disorders Neurology 2005, 65:1941-1949 10.1212/ 01.wnl.0000188869.58300.a7 16380617
42. Weiss M Tannock R Kratochvil C Dunn D Velez-Borras J Thomason C Tamura R Kelsey D Stevens L Allen AJ A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD J Am Acad Child Adolesc Psychiatry 2005, 44(7):647-655 10.1097/ 01.chi.0000163280.47221.c9 15968233
43. Gillberg C Lothgren M Fitzgerald P Cottrell S Burridge J Aristides M Atomoxetine versus methylphenidate as a treatment for ADHD in children and adolescents: A meta-analysis of safety data incorporating active comparator and placebo controlled trials [abstract/poster presentation] European Society for Child and Adolescent Psychiatry (ESCAP): 28 Sep - 1 Oct 2003, Paris, France
44. Schachter HM Pham B King J Langford S Moher D How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis CMAJ 2001, 165(11):1475-1488 81663 11762571
45. Bae JP Meta-regression Analysis of Efficacy in Atomoxetine Randomized Controlled ADHD Trials [Podium presentation] European International Society of Pharmacoeconomic and Outcomes Research (EISPOR): 6-9 Nov 2004, Florence, Italy
46. Kratochvil CJ Heiligenstein JH Dittmann R Spencer TJ Biederman J Wernicke J Newcorn JH Casat C Milton D Michelson D Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial J Am Acad Child Adolesc Psychiatry 2002, 41(7):776-784 10.1097/00004583-200207000-00008 12108801
47. Newcorn JH Kratochvil CJ Allen AJ Casat CD Ruff DD Moore RJ Michelson D Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response Am J Psychiatry 2008, 165(6):721-730 10.1176/ appi.ajp.2007.05091676 18281409
48. Michelson D Buitelaar JK Danckaerts M Gillberg C Spencer TJ Zuddas A Faries DE Zhang S Biederman J Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double-blind, placebo-controlled study J Am Acad Child Adolesc Psychiatry 2004, 43(7):896-904 10.1097/01.chi.0000125089.35109.81 15213591
49. Sacristán JA Oliva J Del Llano J Prieto L Pinto JL What is an efficient health technology in Spain? Gac Sanit 2002, 16:334-343 12113733
50. Schlander M Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness Eur Child Adolesc Psychiatry 2007, 16(7):421-429 10.1007/s00787-007-0615-2 17401606
51. Taylor E Dopfner M Sergeant J Asherson P Banaschewski T Buitelaar J Coghill D Danckaerts M Rothenberger A Sonuga-Barke E et al European clinical guidelines for hyperkinetic disorder - first upgrade Eur Child Adolesc Psychiatry 2004, 13(Suppl 1);I7-30 15322953
52. Foster EM Jensen PS Schlander M Pelham WE Jr Hechtman L Arnold LE Swanson JM Wigal T Treatment for ADHD: Is more complex treatment cost-effective for more complex cases? Health Serv Res 2007, 42(1 Pt 1):165-182 1955245 17355587 10.1111/j.1475-6773.2006.00599.x